NCT04910386 2026-03-25
Multicenter Phase 2 Study of Envafolimab in Biliary Tract Cancers
3D Medicines
Phase 2 Not yet recruiting
Clinical Trials
17 trialsNCT07159217 2025-09-08
Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer
Peking Union Medical College Hospital
Phase 2 Not yet recruiting
NCT07160283 2025-09-08
The Efficacy and Safety of Trilaciclib in Bone Marrow Protection Before Chemotherapy for Advanced Bile Duct Cancer and Pancreatic Cancer
The Second Affiliated Hospital of Shandong First Medical University
Phase 2 Not yet recruiting
NCT07129018 2025-08-19
Trastuzumab Rezetecan Combined With Pertuzumab and Iparomlimab and Tuvonralimab for Biliary Tract Cancer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2 Not yet recruiting
NCT07109167 2025-08-07
The Safety and Efficacy of Benmelstobart Injection in Patients With Advanced Biliary Tract Malignant Tumors
The Second Affiliated Hospital of Shandong First Medical University
Phase 2 Not yet recruiting
NCT07099794 2025-08-01
A Randomized, Two-cohort, Prospective Phase II Clinical Study of the Second-line Treatment of Advanced Biliary System Tumors With Liposomal Irinotecan (II) Combination Regimen
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Not yet recruiting
NCT07030140 2025-06-22
Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma
Shandong Cancer Hospital and Institute
Phase 2 Not yet recruiting
NCT07003815 2025-06-04
Envafolimab With Chemotherapy and Simvastatin in Advanced Biliary Tract Cancer
Tongji Hospital
Phase 2 Not yet recruiting
NCT06993025 2025-05-28
Ivonescimab in Combination With Liposomal Irinotecan and 5-FU/LV in Potentially Resectable Biliary Tract Malignancies
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT06919848 2025-04-09
Oncolytic Virus H101 Combined With Lenvatinib Plus Toripalimab Compared With FOLFOX in Patients With Advanced Biliary Tract Cancer (OPTIONS-06)
Fudan University
Phase 2 Not yet recruiting
NCT06903273 2025-03-30
TisGCS for BTC
National Cheng-Kung University Hospital
Phase 2 Not yet recruiting
NCT06654947 2024-12-16
A Single-arm, Open-label, Prospective Clinical Study of Surufatinib Combined With Immunotherapy and Chemotherapy for Unresectable or Metastatic Biliary Tract Cancer.
Fujian Cancer Hospital
Phase 2 Not yet recruiting
NCT06569225 2024-08-26
NEOLANGIO
University Health Network, Toronto
Phase 2 Not yet recruiting
NCT06531291 2024-07-31
Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation
RenJi Hospital
Phase 2 Not yet recruiting
NCT06502080 2024-07-17
RADITOP
Shanghai Zhongshan Hospital
Phase 2 Not yet recruiting
NCT06389500 2024-04-29
HAIC+Adebrelimab+Lenvatinib for Conversion Treatment of Potentially Resectable, Locally Advanced Biliary Tract Cancer
Harbin Medical University
Phase 2 Not yet recruiting
NCT06037655 2023-09-14
Modified
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Not yet recruiting